OncoMatch/Clinical Trials/NCT05962242
HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma
Is NCT05962242 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for squamous cell carcinoma of the oropharynx.
The study will evaluate the safety and effectiveness of a lower than standard dose of radiation for definitive or adjuvant treatment of head and neck squamous cell carcinomas.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: CDKN2A p16 positive (positive)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Prior history of radiotherapy to the head and/or neck
Cannot have received: surgery
Exception: Participant is eligible if the gross tumor was not completely removed (incomplete oncologic surgery)
Had surgery for oropharyngeal cancer within 8 months of enrollment unless it was an incomplete oncologic surgery
Lab requirements
Liver function
Hepatic insufficiency as determined by the treating clinician resulting in clinical jaundice and/or coagulation effects or severe liver dysfunction [excluded]
Cardiac function
Unstable angina and/or congestive heart failure requiring hospitalization up to 180 days before registration; Transmural myocardial infarction up to 180 days before registration [excluded]
Unstable angina and/or congestive heart failure requiring hospitalization up to 180 days before registration; Transmural myocardial infarction up to 180 days before registration; Hepatic insufficiency as determined by the treating clinician resulting in clinical jaundice and/or coagulation effects or severe liver dysfunction
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Miami Cancer Institute · Miami, Florida
- University of Virginia · Charlottesville, Virginia
- Eastern Virginia Medical School · Norfolk, Virginia
- Bon Secours · Richmond, Virginia
- Virginia Commonwealth University · Richmond, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05962242 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy, surgery disqualifies patients from enrollment.
Does this trial require CDKN2A?
Yes, CDKN2A p16 positive is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify